阿美替尼联合卡铂-培美曲塞对比阿美替尼单药治疗伴抑癌基因共突变EGFR突变NSCLC的III期随机研究(ACROSS2)
ACROSS2是首个前瞻性、多中心、随机III期研究,比较阿美替尼联合卡铂-培美曲塞与阿美替尼单药在EGFR突变伴抑癌基因共突变的晚期NSCLC中的疗效。共入组126例患者,联合组62例,单药组64例。中位随访25.3个月,联合组中位PFS显著延长(19.78 vs 16.53个月;HR 0.58;95%CI 0.34-0.97)。
要点
- 联合组中位PFS 19.78个月,单药组16.53个月,HR 0.58(95%CI 0.34-0.97)。
- TP53共突变亚组显示明确PFS获益。
- 联合组≥3级不良事件发生率25.9%,单药组17.2%,无药物相关死亡。
核心结论
- ACROSS2提供首个前瞻性证据支持在EGFR突变伴抑癌基因共突变的NSCLC中采用基因型导向的化疗联合靶向强化策略,倾向阿美替尼联合卡铂-培美曲塞。
研究设计与样本
- ACROSS2为开放标签、多中心、随机III期研究(NCT04500717),比较阿美替尼联合卡铂-培美曲塞与阿美替尼单药。
- 共入组126例EGFR突变伴抑癌基因共突变的NSCLC患者,随机分配至联合组(n=62)或单药组(n=64)。
- 主要终点为中位无进展生存期(PFS)。
主要发现
- 中位随访25.3个月,联合组中位PFS显著优于单药组(19.78 vs 16.53个月;HR 0.58;95%CI 0.34-0.97)。
- 12、18、24个月PFS率分别为联合组78.7% vs 单药组65.3%、67.2% vs 40.8%、41.0% vs 29.9%。
- 亚组分析显示TP53共突变患者从联合治疗中PFS获益明确。
- 联合组≥3级不良事件发生率25.9%,单药组17.2%;未观察到药物相关死亡。
- 总生存数据不成熟(数据成熟度4%)。
关键数值与推荐
- 主要终点中位PFS:联合组19.78个月 vs 单药组16.53个月,HR 0.58(95%CI 0.34-0.97)。
- 12个月PFS率:联合组78.7% vs 单药组65.3%;18个月:67.2% vs 40.8%;24个月:41.0% vs 29.9%。
- ≥3级不良事件发生率:联合组25.9% vs 单药组17.2%。
临床怎么用
- 对于EGFR突变伴抑癌基因共突变(尤其TP53共突变)的晚期NSCLC患者,可考虑阿美替尼联合卡铂-培美曲塞作为强化一线治疗策略。
- 联合治疗≥3级不良事件发生率高于单药,需权衡获益与毒性。
局限性
- 总生存数据不成熟(数据成熟度4%),无法评估OS获益。
- 样本量较小(共126例),亚组分析需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line therapy for advanced, EGFR-mutated nonsmall cell lung cancer (NSCLC). However, their benefit is limited in patients who have co-existing tumor suppressor gene (TSG) mutations, highlighting a need for intensified strategies to improve outcomes. ACROSS2 (ClinicalTrials.gov identifier NCT04500717) is the first prospective, multicenter, randomized phase 3 study to compare the third-generation EGFR-TKI aumolertinib in combination with carboplatin-pemetrexed versus aumolertinib monotherapy in patients who had NSCLC with EGFR mutations and concomitant TSG mutations. In total, 126 patients were enrolled and randomly assigned to either combination therapy (n = 62) or monotherapy (n = 64). The primary end point was median progression-free survival (PFS). At a median follow-up of 25.3 months, combination therapy significantly prolonged median PFS compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34-0.97). Landmark PFS rates at 12, 18, and 24 months were 78.7% versus 65.3%, 67.2% versus 40.8%, and 41.0% versus 29.9%, respectively. Subgroup analyses demonstrated a clear PFS benefit in patients who had co-existing tumor protein p53 (TP53) mutations. Grade 3 or greater adverse events occurred in 25.9% of patients who received combination therapy versus 17.2% of those who received monotherapy; no drug-related deaths were observed. Overall survival data were immature (data maturity, 4%). The ACROSS2 trial provides the first prospective evidence supporting a genotype-directed, chemotherapy-targeted intensification approach favoring aumolertinib plus carboplatin-pemetrexed for this molecularly defined population.
引用
- Duan JC, Zhong J, Sun BY, et al. Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study. CA Cancer J Clin. 2026. PMID: 41818162. doi:10.3322/caac.70071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。